Excellent response to anti-CD38 therapy with daratumumab in a patient with severe refractory CANOMAD

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Comments (0)

No login
gif